Table 1. IC₅₀ values for doxorubicin and other drugs in cancer cells.

Cells were pretreated with METTL3 siRNA (100 nM), neplanocin A (NPC, 20 nM) or PDMP (5 μM). #, WiDr cells were pretreated with 0.5 μM NPC or 10 μM PDMP. *p<0.001 to SW48 cells; **, p<0.001 compared to vehicle control. Data presented as mean ± SD.

Cell Lines and Pretreatments	Doxorubicin (nM)	Oxaliplatin (μM)	5-Fluorouracil (μM)
SW48-Dox	45.60 ± 8.02	2.21 ± 0.11	6.11 ± 0.79
TP53-Dox	599.9 ± 9.87*	5.30 ± 0.83*	12.5 ± 1.07*
SW48/5-FU	83.60 ± 5.12*	0.95 ± 0.04	7.6 ± 0.85
TP53/5-FU	413 ± 20.8*	11.8 ± 4.39*	17.05 ± 0.92*
WiDr	740.88 ± 23.96*	17.8 ± 0.98*	19.11 ± 0.77*
METTL3 siRNA
SW48-Dox	47.03 ± 3.07
TP53-Dox	55.27 ± 5.13**
Neplanocin A
SW48-Dox	35.6 ± 6.1	1.09 ± 0.1	2.35 ± 0.16
TP53-Dox	51.17 ± 6.21**	2.02 ± 0.37**	7.30 ± 1.02**
WiDr#	259.79 ± 35.81**	9.07 ± 1.57**	7.52 ± 0.57**
PDMP
SW48-Dox	43.27 ± 3.74	2.05 ± 0.09	5.53 ± 0.65
TP53-Dox	49.42 ± 3.84**	2.04 ± 0.31**	4.59 ± 0.15**
WiDr#	484.60 ± 11.23**	12.05 ± 1.68**	13.97 ± 2.73**